Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd (SHA:600721)
China · Delayed Price · Currency is CNY 7.64
-0.13 (-1.67%)
Jun 15, 2026, 2:34 PM CST
SHA:600721 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 357.7 | 387.43 | 383.47 | 366.22 | 346.37 | 278.13 |
Other Revenue | 0.89 | 0.89 | 2.28 | 3.06 | 3.51 | 3.22 |
| 358.59 | 388.32 | 385.76 | 369.28 | 349.88 | 281.35 | |
Revenue Growth (YoY) | -8.48% | 0.66% | 4.46% | 5.54% | 24.36% | 232.84% |
Cost of Revenue | 224.93 | 237.1 | 224.05 | 227.84 | 255.43 | 184.18 |
Gross Profit | 133.65 | 151.22 | 161.71 | 141.44 | 94.45 | 97.17 |
Selling, General & Admin | 66.7 | 67.16 | 68.4 | 73.72 | 78.35 | 64.51 |
Research & Development | 22.23 | 24.38 | 29.55 | 31.87 | 27.48 | 5.25 |
Other Operating Expenses | 5.75 | 5.13 | 5.22 | 5.25 | 4.79 | 4.65 |
Operating Expenses | 97.39 | 101.19 | 131.11 | 127.3 | 127.16 | 83.14 |
Operating Income | 36.26 | 50.03 | 30.59 | 14.14 | -32.71 | 14.04 |
Interest Expense | -0.08 | - | - | - | -0.11 | -0.05 |
Interest & Investment Income | 1.26 | 1.11 | 4.96 | 2.27 | 0.52 | 0.22 |
Currency Exchange Gain (Loss) | -0.07 | -0.07 | -0.05 | -0 | - | - |
Other Non Operating Income (Expenses) | 0.03 | -0.02 | 0.57 | -0.6 | -0.66 | -0.37 |
EBT Excluding Unusual Items | 37.4 | 51.06 | 36.07 | 15.81 | -32.97 | 13.84 |
Gain (Loss) on Sale of Investments | -7.32 | -7.3 | -0.13 | 0.7 | 0.01 | 0.44 |
Gain (Loss) on Sale of Assets | 0 | 0 | 0.09 | 0.01 | 0 | 0.01 |
Asset Writedown | -1.63 | -0.28 | -0.1 | -0.39 | -0.07 | -0.13 |
Legal Settlements | -0.84 | -0.84 | -0.38 | -0.11 | -0.11 | -0.3 |
Other Unusual Items | 1.91 | 1.52 | 1.3 | 0.45 | 1.02 | 48.32 |
Pretax Income | 29.53 | 44.16 | 36.86 | 16.48 | -32.12 | 62.18 |
Income Tax Expense | 2.92 | 3.47 | -4.61 | 3.51 | 2.62 | 2.3 |
Earnings From Continuing Operations | 26.61 | 40.69 | 41.48 | 12.97 | -34.74 | 59.87 |
Minority Interest in Earnings | - | - | - | - | -0.03 | -0.05 |
Net Income | 26.61 | 40.69 | 41.48 | 12.97 | -34.76 | 59.83 |
Net Income to Common | 26.61 | 40.69 | 41.48 | 12.97 | -34.76 | 59.83 |
Net Income Growth | -35.94% | -1.91% | 219.75% | - | - | - |
Shares Outstanding (Basic) | 384 | 384 | 382 | 379 | 376 | 375 |
Shares Outstanding (Diluted) | 384 | 384 | 382 | 379 | 376 | 375 |
Shares Change (YoY) | 0.40% | 0.50% | 0.79% | 0.92% | 0.20% | -3.79% |
EPS (Basic) | 0.07 | 0.11 | 0.11 | 0.03 | -0.09 | 0.16 |
EPS (Diluted) | 0.07 | 0.11 | 0.11 | 0.03 | -0.09 | 0.16 |
EPS Growth | -36.19% | -2.40% | 217.25% | - | - | - |
Free Cash Flow | 23.55 | 12.42 | 55.68 | 44.84 | 50.77 | 28.68 |
Free Cash Flow Per Share | 0.06 | 0.03 | 0.15 | 0.12 | 0.14 | 0.08 |
Dividend Per Share | 0.040 | 0.040 | - | - | - | - |
Gross Margin | 37.27% | 38.94% | 41.92% | 38.30% | 27.00% | 34.54% |
Operating Margin | 10.11% | 12.88% | 7.93% | 3.83% | -9.35% | 4.99% |
Profit Margin | 7.42% | 10.48% | 10.75% | 3.51% | -9.94% | 21.26% |
Free Cash Flow Margin | 6.57% | 3.20% | 14.44% | 12.14% | 14.51% | 10.20% |
EBITDA | 53.95 | 67.84 | 48.9 | 35.41 | -7.13 | 39.18 |
EBITDA Margin | 15.04% | 17.47% | 12.68% | 9.59% | -2.04% | 13.93% |
D&A For EBITDA | 17.68 | 17.81 | 18.3 | 21.27 | 25.58 | 25.14 |
EBIT | 36.26 | 50.03 | 30.59 | 14.14 | -32.71 | 14.04 |
EBIT Margin | 10.11% | 12.88% | 7.93% | 3.83% | -9.35% | 4.99% |
Effective Tax Rate | 9.90% | 7.87% | - | 21.29% | - | 3.70% |
Revenue as Reported | 358.59 | 388.32 | 385.76 | 369.28 | 349.88 | 281.35 |
Advertising Expenses | - | 1.35 | 0.14 | 1.09 | 0.84 | 0.4 |